Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the...

The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW YORK, June 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a...

The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints NEW YORK, May 3, 2022 /PRNewswire/ -- Hoth...

HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and traumatic brain injury NEW YORK,...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 8,235,294 shares of...

Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer's disease NEW YORK, April 12, 2022 /PRNewswire/ -- Hoth...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering. EF Hutton, division of Benchmark Investments,...

Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft...

Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease Therapeutic NEW YORK,

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for its cancer therapeutic, HT-KIT after receiving Orphan Drug Designation...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) designated HT-KIT, a new molecular entity, as an...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC...

Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of...